Cambridge Innovation Capital
22 Station Road, Cambridge, Cambridgeshire, CB1 2JD, United Kingdom
Overview
Investor in disruptive deep-tech life sciences and technology companies.
Founded
2013
Deals · 12mo
4
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Trent AI | Apr 2026Led | $13 MSeed | |
Immutrin | Mar 2026Participated | $87 MSeries A | |
BeyondMath | Feb 2026Led | $10 MSeed | |
T-Therapeutics | Nov 2025Participated | $32 MSeries A | |
TRIMTECH Therapeutics | Mar 2025Led | $34 MSeed | |
Cambridge GaN Devices | Feb 2025Participated | $32 MSeries C | |
Salience Labs | Feb 2025Participated | $30 MSeries A | |
Forefront RF | Nov 2024Participated | $21 MOther Equity | |
Epitopea | Oct 2024Participated | $31 MSeries A | |
Nuclera | Oct 2024Participated | $77 MSeries C | |
Riverlane | Aug 2024Participated | $75 MSeries C | |
Pragmatic Semiconductor | Dec 2023Participated | $204 MSeries D | |
Trent AI | Apr 2026Led | $13 MSeed | |
Immutrin | Mar 2026Participated | $87 MSeries A | |
BeyondMath | Feb 2026Led | $10 MSeed | |
T-Therapeutics | Nov 2025Participated | $32 MSeries A | |
TRIMTECH Therapeutics | Mar 2025Led | $34 MSeed | |
Cambridge GaN Devices | Feb 2025Participated | $32 MSeries C | |
Salience Labs | Feb 2025Participated | $30 MSeries A | |
Forefront RF | Nov 2024Participated | $21 MOther Equity | |
Epitopea | Oct 2024Participated | $31 MSeries A | |
Nuclera | Oct 2024Participated | $77 MSeries C | |
Riverlane | Aug 2024Participated | $75 MSeries C | |
Pragmatic Semiconductor | Dec 2023Participated | $204 MSeries D |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 7 | 4 |
| Series A | 9 | 17 |
| Series B | 2 | 14 |
| Series C+ | 0 | 9 |
| Other Equity | 5 | 11 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Sep '14 | 4 |
| Oct '14 | 0 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 1 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 1 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 1 |
| Nov '15 | 0 |
| Dec '15 | 1 |
| Jan '16 | 2 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 1 |
| May '16 | 0 |
| Jun '16 | 1 |
| Jul '16 | 1 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 4 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 1 |
| Feb '17 | 1 |
| Mar '17 | 0 |
| Apr '17 | 0 |
| May '17 | 1 |
| Jun '17 | 1 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 2 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 1 |
| Mar '18 | 1 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 1 |
| Jul '18 | 2 |
| Aug '18 | 0 |
| Sep '18 | 2 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 1 |
| Feb '19 | 2 |
| Mar '19 | 1 |
| Apr '19 | 2 |
| May '19 | 1 |
| Jun '19 | 3 |
| Jul '19 | 1 |
| Aug '19 | 0 |
| Sep '19 | 1 |
| Oct '19 | 1 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 2 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 1 |
| Nov '20 | 2 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 1 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 1 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 1 |
| Apr '22 | 1 |
| May '22 | 1 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 2 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 1 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 3 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 1 |
| Oct '23 | 0 |
| Nov '23 | 2 |
| Dec '23 | 1 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 1 |
| Sep '24 | 0 |
| Oct '24 | 2 |
| Nov '24 | 1 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 2 |
| Mar '25 | 1 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 1 |
| Mar '26 | 1 |
| Apr '26 | 1 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 38 |
| Hardware & Robotics | 18 |
| Enterprise Software | 13 |
| AI & Machine Learning | 12 |
| Space & Frontier Tech | 11 |
| Networks, Cloud & Communication | 11 |
| Data, Analytics & IT | 10 |
| Media & Entertainment | 9 |
| Developer Tools | 5 |
| Manufacturing | 4 |
| Transportation & Logistics | 3 |
| Consumer & Lifestyle | 3 |
| Marketing & Advertising | 3 |
| Professional Services | 3 |
| Cybersecurity & Privacy | 2 |
| Clean Energy & Sustainability | 2 |
| Fintech | 2 |
| AR/VR | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 10 |
| $5M-$10M | 15 |
| $10M-$25M | 24 |
| $25M-$50M | 11 |
| $50M-$100M | 12 |
| $100M-$250M | 5 |
| $250M-$500M | 0 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 3 of 3 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 67 |
| United States | 7 |
| Cb1 2la | 4 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Cambridge Enterprise | 15 |
| Parkwalk Advisors | 14 |
| Amadeus Capital Partners | 12 |
| Tencent | 7 |
| Global Brain | 5 |
| Watrium | 5 |
| BGF | 4 |
| British Patient Capital | 4 |
| IQ Capital | 4 |
| LGT | 4 |
| Martlet Capital | 4 |
| Octopus Ventures | 4 |
| 31 Ventures | 3 |
| ARCH Venture Partners | 3 |
| Arm | 3 |
| Atlantic Bridge | 3 |
| Cambridge Angels | 3 |
| Digitalis Ventures | 3 |
| F-Prime Capital | 3 |
| Google Ventures | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 23 | 29% |
| Participating | 55 | 71% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 11 | 48% |
| Co-led | 12 | 52% |
Team
Partner
Principal
Independent Non-executive Director
Operating Partner
Partner
Investment Director
Partner
Partner